Shopping Cart 0
Cart Subtotal
USD 0

Surface Oncology Inc (SURF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Surface Oncology Inc (Surface Oncology) is an immuno-oncology company that develops novel antibody therapies for the treatment of cancer. The company's lead product candidate SRF231 is a human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells which prevents them from being engulfed and eliminated by macrophages. It conducts pre-clinical study through new approaches to enhance the effectiveness of antigen presentation; restrict the activity of suppressor cells in the tumor microenvironment; and to counter the effect of specific inhibitory cytokines and metabolites. Surface Oncology also provides monotherapies, checkpoint inhibitors and cancer vaccines. The company also develops pipeline of next-generation immunotherapies that provides treatment for patients suffering from cancer. Surface Oncology is headquartered in Cambridge, Massachusetts, the US.

Surface Oncology Inc (SURF)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Surface Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Surface Oncology Raises USD35 Million in Series A Financing 10

Surface Oncology Raises Funds through Seed Financing 12

Partnerships 13

ProBioGen Enters into Agreement with Surface Oncology 13

Adimab Enters into Agreement with Surface Oncology 14

Licensing Agreements 15

Surface Oncology Enters into Research and License Option Agreement with Vaccinex 15

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 16

Surface Oncology Enters into Licensing Agreement with Novartis 17

Surface Oncology Enters into Licensing Agreement with Harbour Antibodies for CD47 18

Surface Oncology Enters into Licensing Agreement with Harbour Antibodies for H2L2 19

Equity Offering 20

Surface Oncology Raises USD11.5 Million in Private Placement of Shares 20

Surface Oncology Raises USD108 Million in IPO 21

Surface Oncology Inc-Key Competitors 22

Surface Oncology Inc-Key Employees 23

Surface Oncology Inc-Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

Financial Announcements 25

Aug 14, 2018: Surface Oncology reports financial results and corporate highlights for second quarter 2018 25

May 29, 2018: Surface Oncology Reports Financial Results For First Quarter 2018 27

Corporate Communications 28

Feb 22, 2018: Surface Oncology Expands Board Of Directors 28

Feb 12, 2018: Surface Oncology Promotes Jeff Goater to Chief Executive Officer 29

Jun 19, 2017: Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts 30

Feb 06, 2017: Surface Oncology Appoints Jeff Goater as Chief Business Officer 31

Jan 04, 2017: Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Surface Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Surface Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Surface Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Surface Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Surface Oncology Raises USD35 Million in Series A Financing 10

Surface Oncology Raises Funds through Seed Financing 12

ProBioGen Enters into Agreement with Surface Oncology 13

Adimab Enters into Agreement with Surface Oncology 14

Surface Oncology Enters into Research and License Option Agreement with Vaccinex 15

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 16

Surface Oncology Enters into Licensing Agreement with Novartis 17

Surface Oncology Enters into Licensing Agreement with Harbour Antibodies for CD47 18

Surface Oncology Enters into Licensing Agreement with Harbour Antibodies for H2L2 19

Surface Oncology Raises USD11.5 Million in Private Placement of Shares 20

Surface Oncology Raises USD108 Million in IPO 21

Surface Oncology Inc, Key Competitors 22

Surface Oncology Inc, Key Employees 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Surface Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.